Cutia Therapeutics (02487.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 1.32

From 52W high−89.09%

Volume759000.00

Market capHKD 437.64M

P/E (TTM)—

P/S (TTM)1.1x

Div yield—

Key dataSep 18, 2026

Open

HKD 1.32

From 52W high

−89.09%

Volume

759000.00

Market cap

HKD 437.64M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

P/E (TTM)

—

RSI (14)

18.6

MomentumView details →

1D Return

−11.76%

YTD Return

−73.57%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.1x

EV/Sales

0.1x

P/S (TTM)

1.1x

P/B (TTM)

0.5x

ProfitabilityView details →

Gross Margin

53.59%

Net Margin

−84.59%

EBITDA Margin

−65.06%

ROE (TTM)

−39.55%

ROA (TTM)

−26.20%

Asset Turnover

0.28x

GrowthView details →

Revenue YoY

+32.88%

EPS YoY

+48.03%

FCF YoY

+69.69%

Revenue CAGR 3Y

+209.25%

EPS CAGR 3Y

+26.95%

EBITDA YoY

+48.81%

MomentumView details →

1D Return

−11.76%

YTD Return

−73.57%

1Y Return

−87.32%

RSI (14)

18.6

vs 50D SMA

−43.36%

vs 200D SMA

−69.71%

Capital & dividendView details →

Debt/Equity

0.39x

Current Ratio

3.85x

Quick Ratio

3.78x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.58

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

−0.21%

Financials snapshotView financials →

Revenue (TTM)

582.97M

Net Income (TTM)

−753.67M

Op. CF (TTM)

−503.02M

Next earningsMar 30, 2027 →

Latest newsMore news →

Cutia's Biologics License Application for CU-20101 was accepted for review by China's National Medical Products Administration.18d ago

Cutia Group reported interim results for the six months ended June 2026, with revenue of RMB 62.71 million, down 5.4% year-on-year, and a narrowed net loss of RMB 180 million compared to RMB 239 million in the prior-year period.20d ago

Similar companies

Relmada Therapeutics, Inc.RLMD Prothena Corporation plcPRTA Kyverna Therapeutics, Inc.KYTX Cabaletta Bio, Inc.CABA Opus Genetics, Inc.IRD Genfit S.A.GNFT Find similar companies →

Latest newsMore news →

Cutia's Biologics License Application for CU-20101 was accepted for review by China's National Medical Products Administration.18d ago Cutia Group reported interim results for the six months ended June 2026, with revenue of RMB 62.71 million, down 5.4% year-on-year, and a narrowed net loss of RMB 180 million compared to RMB 239 million in the prior-year period.20d ago